Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director


The bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces

Claudia D'Augusta is a seasoned financial professional with more than 20 years’ experience in corporate finance, capital markets and M&A. She is currently Chief Financial Officer at TiGenix N.V. and is part of the management team at TiGenix, which Takeda has announced its intention to acquire for EUR 520 million. Prior to TiGenix, Claudia D'Augusta held various other senior financial positions across a number of international public and private companies.

Claudia D’Augusta replaces Wim Goemaere, formerly Chief Financial Officer, who will step down as a Non-Executive Director of the Company.

Claudia D'Augusta holds a degree in Economics and a Ph.D. in Business Administration from the University of Bocconi, Milan, Italy.


Welcoming Claudia D’Augusta to the Bone Therapeutics Board, Jean Stéphenne, Chairman, said: "We are delighted to welcome Claudia D’Augusta to the Board of Directors. I have had the privilege of working with Claudia at TiGenix where she proved an extremely able Chief Financial Officer. I am confident Claudia will provide further valuable financial guidance and support as we continue to progress the Company towards commercialization.”

“On behalf of the Board and leadership team of Bone Therapeutics, I would like to extend my thanks to Wim Goemaere, who was a capable and supportive member of our management team and Board through many pivotal moments in the Company’s development. We wish him all the best with his future endeavours.”

Claudia D’Augusta, commented: “I’m pleased to join to the Board of Bone Therapeutics at this exciting time in the Company’s development. I believe Bone Therapeutics products have the potential to revolutionize the field of orthopaedics and bone diseases and I am looking forward to contributing to the Company’s future success.”


Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
The Company’s primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at:



Interested in a regular update of the Life Sciences and biotech sector in Flanders?